Takeda Pharmaceutical Co. and H. Lundbeck AS have taken Torrent Pharmaceuticals Ltd. and Sigmapharm Laboratories LLC to court in a continued push to protect Trintellix from generic competition.
Takeda and Lundbeck co-market Trintellix (vortioxetine hydrobromide), which treats major depressive disorder. They’ve filed separate Hatch-Waxman Act lawsuits against Torrent and Sigmapharm in Delaware, alleging their generic versions infringed a total of six patents. Their suit against Sigmapharm, based in Bensalem, Pa., alleges its generic version of Trintellix infringes all six. Their suit against Torrent, based in Ahmedabad, India, alleges infringement of one of those.
The new suits are part of an ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.